Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: J Heart Lung Transplant. 2015 Jun 10;34(11):1415–1422. doi: 10.1016/j.healun.2015.06.003

Figure 3.

Figure 3

Freedom from chronic lung allograft dysfunction (CLAD) and graft survival. A. There was no significant difference in freedom from CLAD between recipients who were allosensitized and those who were not. B. There was no significant difference in freedom from CLAD between recipients who were allosensitized with a CPRA > 50%, those with a CPRA between 1–50%, and those who were not allosensitized. C. There was no significant difference in graft survival between recipients who were allosensitized and those who were not. D. There was no significant difference in graft survival between those with a CPRA > 50%, those with a CPRA between 1–50%, and those who were not allosensitized.